Jump to main content
Jump to site search

Issue 6, 2013
Previous Article Next Article

Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs

Author affiliations

Abstract

Over the past six decades, the folate biosynthetic pathway has provided a rich source of drug targets for the treatment of proliferative diseases. Drugs targeting dihydrofolate reductase have been especially successful as anticancer (methotrexate), antibacterial (trimethoprim, TMP) and antiprotozoal (cycloguanil, pyrimethamine) therapeutics. While trimethoprim remains a clinically important antimicrobial DHFR inhibitor, resistance by point mutations in otherwise sensitive strains as well as the natural insensitivity of several species limits its use. In this review, an historical overview of the attempts to develop drugs that target the folate pathway is presented along with a discussion of the basis of insensitivity to trimethoprim. From this vantage, we have developed the propargyl-linked antifolates as potent inhibitors of TMP-insensitive enzymes and strains. The structural basis of the increased affinity is detailed to promote the development of further generations of antifolates.

Graphical abstract: Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs

Back to tab navigation

Article information


Submitted
04 Apr 2013
Accepted
22 Apr 2013
First published
25 Apr 2013

Med. Chem. Commun., 2013,4, 908-915
Article type
Review Article

Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs

W. Zhou, E. W. Scocchera, D. L. Wright and A. C. Anderson, Med. Chem. Commun., 2013, 4, 908
DOI: 10.1039/C3MD00104K

Search articles by author

Spotlight

Advertisements